60 Degrees Pharmaceuticals (SXTP) Debt to Equity (2022 - 2025)
Historic Debt to Equity for 60 Degrees Pharmaceuticals (SXTP) over the last 4 years, with Q3 2025 value amounting to $0.18.
- 60 Degrees Pharmaceuticals' Debt to Equity rose 7203.53% to $0.18 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.18, marking a year-over-year increase of 7203.53%. This contributed to the annual value of $0.16 for FY2024, which is 6697.11% down from last year.
- Per 60 Degrees Pharmaceuticals' latest filing, its Debt to Equity stood at $0.18 for Q3 2025, which was up 7203.53% from $0.33 recorded in Q2 2025.
- 60 Degrees Pharmaceuticals' Debt to Equity's 5-year high stood at $0.48 during Q4 2023, with a 5-year trough of -$1.0 in Q2 2023.
- Over the past 4 years, 60 Degrees Pharmaceuticals' median Debt to Equity value was $0.16 (recorded in 2024), while the average stood at $0.08.
- As far as peak fluctuations go, 60 Degrees Pharmaceuticals' Debt to Equity surged by 54586.39% in 2023, and later crashed by 6864.8% in 2024.
- Quarter analysis of 4 years shows 60 Degrees Pharmaceuticals' Debt to Equity stood at -$0.11 in 2022, then soared by 545.86% to $0.48 in 2023, then tumbled by 66.97% to $0.16 in 2024, then grew by 13.33% to $0.18 in 2025.
- Its last three reported values are $0.18 in Q3 2025, $0.33 for Q2 2025, and $0.16 during Q1 2025.